WILEX AG Patent applications |
Patent application number | Title | Published |
20160002350 | CAIX STRATIFICATION BASED ON CANCER TREATMENT - The present invention relates to a carbonic anhydrase IX targeting compound for the use in the treatment of cancer, wherein the use comprises quantifying CAIX expression as well as the determination of a CAIX score based on the CAIX expression. The present invention relates further to a method for diagnosing, predicting and/or classifying a cancer disease comprising quantifying CAIX expression, and the determination of a CAIX score. | 01-07-2016 |
20140017252 | BINDING EPITOPES FOR G250 ANTIBODY - The invention relates to specific amino acid sequences which have been determined to be target epitope for antibodies, in particular, for a G250 antibody. | 01-16-2014 |
20120207672 | SELECTIVE DETECTION OF BONE METASTASES IN RENAL CLEAR CELL CARCINOMA - The present invention refers to the detection of bone metastases in renal cell carcinoma (RCC) and suitable reagents therefore using a | 08-16-2012 |
20120165287 | COMBINED TREATMENT OF CANCER BY UROKINASE INHIBITION AND A CYTOSTATIC ANTI-CANCER AGENT FOR ENHANCING THE ANTI-METASTATIC EFFECT - The present invention relates to a combined treatment of cancer using a urokinase inhibitor and a cytotoxic or a cytostatic agent. | 06-28-2012 |
20120065398 | METHOD FOR PRODUCING 3-AMIDINOPHENYLALANINE DERIVATIVES - The present invention describes a method for the synthesis of enantiomerically pure 3-amidinophenylalanine derivatives, which are used as pharmaceutically effective urokinase inhibitors, by starting from 3-cyanophenylalanine derivatives. The methods of manufacture comprising only one synthesis step lead to new intermediates, namely 3-hydroxyamidino- and 3-amidrazonophenylalanine derivatives. These intermediates or their acetyl derivatives can be reduced into the desired 3-amidino-phenylalanine derivatives under gentle conditions (H | 03-15-2012 |
20110123537 | BINDING EPITOPES FOR G250 ANTIBODY - The invention relates to specific amino acid sequences which have been determined to be target epitope for antibodies, in particular, for a G250 antibody. | 05-26-2011 |
20110087025 | METHOD FOR PRODUCING 3-AMIDINOPHENYLALANINE DERIVATIVES - The present invention describes a method for the synthesis of enantiomerically pure 3-amidinophenylalanine derivatives, which are used as pharmaceutically effective urokinase inhibitors, by starting from 3-cyanophenylalanine derivatives. The methods of manufacture comprising only one synthesis step lead to new intermediates, namely 3-hydroxyamidino- and 3-amidrazonophenylalanine derivatives. These intermediates or their acetyl derivatives can be reduced into the desired 3-amidino-phenylalanine derivatives under gentle conditions (H | 04-14-2011 |
20100068272 | HYDROXYAMIDINE AND HYDROXYGUANIDINE COMPOUNDS AS UROKINASE INHIBITORS - The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups. | 03-18-2010 |
20100008888 | CO-ADMINISTRATION OF CG250 AND IL-2 OR IFN-ALPHA FOR TREATING CANCER SUCH AS RENAL CELL CARCINOMAS - A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose of cytokine in combination with antibodies directed against the tumor associated antigen carbonic anhydrase IX (CAIX/G250/MN). The improved treatment method is characterized in a significantly reduced cytokine-related toxicity combined with potentiated effectiveness of anti-G250 antibody alone, resulting in a positive therapeutic response with respect to that observed with single anti-tumor agents alone. | 01-14-2010 |
20090274620 | Hybridoma Cell Line G250 and its use for Producing Monoclonal Antibodies - This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives thereof such as chimeric and humanized G250 antibodies | 11-05-2009 |
20090202550 | MONOCLONAL ANTIBODIES AND IMMUNODETECTION ASSAY SPECIFIC FOR THE CHEMOTACTIC EPITOPE OF THE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR - The present invention describes monoclonal antibodies specific for the chemotactic epitope of the uPAR. In particular, the invention comprises monoclonal antibodies against uPAR fragments specifically recognizing in whole or in part the chemotactic sequence of uPAR connecting domain 1 to domain 2. | 08-13-2009 |
20090202504 | METHODS FOR THE DETECTION AND PROGNOSIS OF BREAST TUMORS - This invention relates to the production of specific antibodies for the detection of human tumor associated urokinase-type plasminogen activator receptor (uPAR) deletion variants in biological samples as well as to their diagnostic and therapeutic application. | 08-13-2009 |
20090099360 | Method for Cleaning 3-Hydroxyamidinophenylalanine Derivatives by the Precepitation and Recrystallization of Salt and an Aromatic Sulfonic Acid - The present invention relates to the preparation of 3-hydroxyamidino-phenylalanine derivatives in highly pure form which can be used for example as urokinase inhibitors. The present invention further relates to the use of high-purity 3-hydroxyamidinophenylalanine derivatives for preparing 3-amidinophenylalanine derivatives. | 04-16-2009 |
20090005562 | Method for the Production of Phenylalanine Derivatives - The invention relates to an improved method for the production of 3-amidino- or 3-guanidinophenylalanine derivatives, especially triisopropylphenyl-sulfonyl-substituted 3-amidino- or 3-guanidinophenylalanine derivatives. | 01-01-2009 |
20080261998 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors - The present invention relates to novel compounds for inhibiting the urokinase plasminogen activator (uPA), which have high bioavailability and oral administerability, and also to the use thereof as therapeutic active compounds for the treatment of urokinase- or/and urokinase receptor-associated disorders such as, for example, tumors and metastasizing. The invention relates in particular to compounds containing hydroxyamidine or hydroxyguanidine groups. | 10-23-2008 |